Dr Martin Mackay
Co-FounderMartin serves in an executive leadership role at Rallybio, overseeing all research and non-research functions. He has more than 30 years of experience in drug discovery and development, overseeing multinational teams working on hundreds of programs. Most recently, he was Executive Vice President, Global Head of R&D at Alexion Pharmaceuticals, where he oversaw the development of multiple pre-clinical and clinical programs, resulting in new ultra-rare indications, for Soliris® (eculizumab), as well as new approvals for the ultra-orphan therapies Strensiq® (asfotase alfa) and Kanuma® (sebelipase alfa).
Prior to Alexion, Martin served as President, Research and Development at AstraZeneca, reporting directly to the CEO, where he led all R&D functions on a global basis, from discovery research through clinical development, regulatory affairs and related functions. Prior to AstraZeneca, he held positions of increasing responsibility at Pfizer, rising to the position of President, Head of Pfizer Pharmatherapeutics, R&D, working across nine therapeutic areas and reporting to the CEO and Chairman.
Martin serves on the Boards of Directors of Charles River Laboratories and Novo Nordisk. He obtained a First Class Honours degree in Microbiology from Heriot-Watt University and his PhD in molecular genetics from the University of Edinburgh, Scotland.
Dr Stephen Uden
Co-FounderSteve oversees all of Rallybio’s scientific research and development operations. He has more than 25 years of experience, serving in R&D leadership roles with prominent global pharmaceutical and biotech firms. Steve was previously head of research at Alexion Pharmaceuticals where he led a series of collaborations and external alliances, expanded its research base beyond antibodies to include small molecules, RNA-based therapies and broader protein engineering capabilities. Under Steve, Alexion expanded its research portfolio to more than 30 pre-clinical and clinical programs.
Prior to Alexion, Steve led Wyeth’s research and development group and Novartis Oncology’s development programs, both roles based in Japan. During his 6 years in Japan, he led his teams to more than 10 J-NDA approvals. Prior to Wyeth, Steve held positions of increasing responsibility at Pfizer, where he rose to leadership in the UK, Japan, and the US. In addition, he also led research and development at Neurogen, a biotech company developing small molecule candidates.
Steve received his medical training at the University of London’s St. Thomas’ Hospital Medical School, and then practiced clinical and academic medicine within the UK National Health Service and the University of Manchester UK.
Jeffrey Fryer CPA
Co-FounderJeff oversees all financial, administrative and support functions for Rallybio, including financial management, information technology, human resources, facilities and investor relations. He has more than 25 years of experience in business finance and the economics of operations, as well as corporate strategy and taxation. Jeff was previously Vice President, Chief Tax Officer with Alexion Pharmaceuticals, where he was a member of the financial leadership team. He led the design of the organizational structure, implementation, and ongoing monitoring of the global operating principles, with an emphasis on driving financial operational efficiency.
Prior to Alexion, Jeff was a member of the finance organizations of Chemtura Corporation and Lydall, Inc. He began his career in public accounting with PriceWaterhouseCoopers.
Jeff serves as Chairman of the Board of Directors of Holy Cross High School, Waterbury, CT and is also a member of the Dean’s Advisory Council for the Bryant University School of Business. He earned a Master of Science in Taxation from the University of Hartford and a Bachelor of Science in Business Administration with a Concentration in accounting from Bryant University. Jeff is a frequent lecturer at university and professional conferences on finance and tax related topics.